Tianjin Ringpu Bio-Technology Co Ltd

Tianjin Ringpu Bio-Technology maintains a market capitalization of 7.9 billion CNY and trades at a price-to-earnings ratio of 19.72, which is above the industry median of 15.2. The company's price-to-book ratio of 1.68 suggests a moderate premium to its book value, while its enterprise value to EBITDA of 19.62 is in line with the industry median of 18.9. The company's liquidity position is characterized by a current ratio of 1.79, indicating a moderate ability to meet short-term obligations, and a debt-to-equity ratio of 0.32, which is below the industry median of 0.45. The company's profitability is reflected in a return on equity of 8.52% and a return on assets of 5.23%, both of which are below the industry median of 10.1% and 6.8%, respectively. Gross margin stands at 41.1%, which is in line with the industry median of 40.9%, but operating margin of 14.1% is below the median of 16.3%. Net income of 400.5 million CNY for the latest period represents a 12.3% margin on revenue of 3.4 billion CNY. Geographically, the company's revenue is concentrated in China, with no material international operations disclosed. Segment-wise, the company operates as a single business unit, with no material diversification across product lines or therapeutic areas. This lack of diversification increases exposure to domestic regulatory and market risks. Looking ahead, the company is projected to grow revenue by 8.2% in the current fiscal year and 6.5% in the next, based on analyst estimates and historical performance. Free cash flow of 310.5 million CNY and operating cash flow of 297.5 million CNY indicate a stable cash generation profile, though capital expenditures of 176.1 million CNY suggest ongoing investment in operations. The company faces moderate liquidity risk due to a net cash position that is negative after subtracting total debt. Dilution risk is assessed as low, with no significant dilutive events disclosed in the latest filings. The company's credit risk is moderate, supported by a strong equity base and manageable debt levels. Recent filings and transcripts indicate that the company is focused on expanding its product pipeline and enhancing R&D capabilities. No material legal or regulatory issues have been disclosed in the latest 10-K or investor presentations. The company's recent performance has attracted analyst attention, with a mean price target of 20.41 CNY and a median price target of 23.00 CNY.